Corticosteroid withdrawal after renal transplantation in the cyclosporin era. Timing, benefits and risks

BioDrugs

Volumn 8, Issue 2, 1997, Pages 139-149

  Hricik, Donald E ^a,b   Schulak, James A ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

CORTICOSTEROID THERAPY; DRUG WITHDRAWAL; FOLLOW UP; GRAFT REJECTION; GROWTH DISORDER; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; REVIEW;

EID: 0030789570     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199708020-00007     Document Type: Review

References (96)

1. Starzl TE, Marchioro TL, Waddel WR. The reversal of rejection in renal homografts with subsequent development of homograft tolerance. Surg Gynecol Obstet 1963; 117: 385-95
2. Hricik DE, Almawi WY, Strom TB. Trends in the use of glucocorticoids in renal transplantation. Transplantation 1944; 57: 979-89
3. Fauci AS. The effect of hydrocortisone on the kinetics of normal human lymphocytes. Blood 1975; 46: 235-40
4. Knudsen PJ, Dinarello CA, Strom TB. Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells. J Immunol 1987; 139: 4129-34
5. Kern JA, Lamb RJ, Reed JC, et al. Dexamethasone inhibition of interleukin 1 beta production by human monocytes: postranscriptional mechanisms. J Clin Invest 1988; 81: 237-44
6. Zanker B, Walz G, Wieder KJ, et al. Evidence that glucocorticoids block expression of the human interleukin-6 gene by accessory cells. Transplantation 1990; 49: 183-5
7. Ray A, Sehgal PB. Cytokines and their receptors: molecular mechanism of interleukin-6 gene repression by glucocorticoids. J Am Soc Nephrol 1992; 2 (Suppl.): S214-21
8. Culpepper JA, Lee F. Regulation of IL-3 expression by glucocorticoids in cloned murine T lymphocytes. J Immunol 1985; 135: 3191-7
9. Gessani S, McCandless S, Baglioni C. The glucocorticoid dexamethasone inhibits synthesis of interferon by decreasing the level of its mRNA. J Biol Chem 1988; 263: 7454-7
10. Arya SK, Wong-Staal F, Gallo RC. Dexamethasone-mediated inhibition of human T cell growth factor and gamma interferon messenger RNA. J Immunol 1984; 133: 273-6
11. Waage A, Baake O. Glucocorticoids suppress the production of tumour necrosis factor by lipopolysaccharide-stimulated human monocytes. Immunology 1988; 63: 299-302
12. Granelli-Piperno A, Nolan P, Inaba K, et al. The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites in the interleukin 2 promoter. J Exp Med 1990; 172: 1869-72
13. Vacca A, Felli MP, Farina AR, et al. Glucocorticoid receptor-mediated suppression of the interleukin 2 gene expression through impairment of the cooperatively between nuclear factor of activated T cells and AP-1 enhancer elements. J Exp Med 1992; 175: 637-46
14. Shen V, Cheng SL, Kohler NG, et al. Characterization and hormonal modulation of IL-1 binding in neonatal mouse osteoblast-like cells. J Bone Miner Res 1990; 5: 507-15
15. Schooltink H, Schmitz-Van de Leur H, Heinrich PC, et al. Up-regulation of the interleukin-6-signal transducing protein (gp130) by interleukin-6 and dexamethasone in HepG2 cells. FEBS Lett 1992; 297: 263-5
16. Strickland RW, Wahl LM, Finbloom DS. Corticosteroids enhance the binding of recombinant interferon gamma to cultured monocytes. J Immunol 1986; 137: 1577-80
17. European Mulicentre Trial Group. Cyclosporine in cadaveric renal transplantation: one-year follow-up of a multicentre trial. Lancet 1983; 2: 986-8
18. Calne RY. Cyclosporin in cadaveric renal transplantation: 5-year follow up of a multicentre trial. Lancet 1987; II: 506-8
19. Bry W, Warvariv V, Bohannon L, et al. Cadaveric renal transplant without prophylactic prednisone therapy. Transplant Proc 1991; 23: 994-6
20. Tarantino A, Aroldi A, Stucchi L, et al. A randomized prospective trial comparing cyclosporine monotherapy with triple-drug therapy in renal transplantation. Transplantation 1991; 52: 53-7
21. Schulak JA, Mayes JT, Moritz CE, et al. A prospective randomized trial of prednisone versus no prednisone maintenance therapy in cyclosporine-treated and azathioprine-treated renal transplant recipients. Transplantation 1990; 49: 327-32
22. Stratta RJ, Armbrust MJ, Oh CS, et al. Withdrawal of steroid immunosuppression in renal transplant recipients. Transplantation 1988; 45: 323-8
23. Hricik DE, Whalen CC, Lautman J, et al. Withdrawal of steroids after renal transplantation - clinical predictors of outcome. Transplantation 1992; 53: 41-5
24. Hricik DE, Seliga RM, Fleming-Brooks S, et al. Determinants of long-term allograft function following steroid withdrawal in renal transplant recipients. Clin Transplant 1995; 9: 419-23
25. Julian BA, Laskow DA, Dubovsky J, et al. Rapid loss of vertebral bone density after renal transplantation. N Engl J Med 1991; 325: 544-50
26. Matsunami C, Hilton AF, Dyer JA, et al. Ocular complications in renal transplant patients. Aust NZ J Ophthalmol 1994; 22: 53-7
27. Travis LB, Chesney R, McEnery P, et al. Growth and glucocorticoids in children with kidney disease. Kidney Int 1978; 14: 365-8
28. Tejani A, Butt KMH, Rajpoot D, et al. Strategies for optimizing growth in children with kidney transplants. Transplantation 1989; 47: 229-33
29. Reisman L, Lieberman KV, Burrows L, et al. Follow-up of cyclosporine-treated pediatric renal allograft recipients after cessation of prednisone. Transplantation 1990; 49: 76-80
30. Klare B, Strom TM, Hahn H, et al. Remarkable long-term prognosis and excellent growth in kidney-transplant children under cyclosporine monotherapy. Transplant Proc 1991; 23: 1013-7
31. David-Neto E, Vilares S, Lando V, et al. Conversion from azathioprine/prednisone to azathioprine/cyclosporin promotes catch-up growth in pediatric renal allograft recipients. Clin Transplant 1990; 4: 229-34
32. Nielsen HE. Bone mineral content in renal transplant patients. Clin Nephrol 1978; 10: 196-200
33. Movsowitz C, Epstein S, Fallon M, et al. Cyclosporine-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 1988; 123: 2571-7
34. Wolpaw T, Deal CL, Fleming-Brooks S, et al. Factors influencing vertebral bone density after renal transplantation. Transplantation 1994; 58: 1186-9
35. Briner VA, Thiel G, Monier-Faugere MC, et al. Prevention of cancellous bone loss but persistence of renal bone disease despite normal 1,25-vitamin D levels two years after kidney transplantation. Transplantation 1995; 59: 1393-400
36. Waltzer WC, Turner S, Frohner P, et al. Etiology and pathogenesis of hypertension following renal transplantation. Nephron 1986; 42: 102-10
37. Coles GA, Jones GR, Crosby DL, et al. Hypertension following cadaveric renal transplantation. Postgrad Med J 1972; 48: 399-407
38. Bachy C, Alexandre GPJ, Van Ypersele de Strihou C. Hypertension after renal transplantation. BMJ 1976; 2: 1287-9
39. Rao TKS, Gupta SK, Butt KH, et al. Relationship of renal transplantation to hypertension in end-stage renal failure. Arch Intern Med 1978; 138: 1236-40
40. Kasiske BL. Possible causes and consequences of hypertension in stable renal transplant patients. Transplantation 1987; 44: 639-45
41. Ingulli E, Tejani A, Markell M. The beneficial effects of steroid withdrawal on blood pressure and lipid profile in children posttransplantation in the cyclosporine era. Transplantation 1993; 55: 102-10
42. Kupin W, Venkat KK, Oh OK, et al. Complete replacement of methylprednisolone by azathioprine in cyclosporine-treated primary cadaveric renal transplant recipients. Transplantation 1988; 45: 53-7
43. Pirsch JD, Armbrust MJ, Knechtle SJ, et al. Effect of steroid withdrawal on hypertension and cholesterol levels in living related recipients. Transplant Proc 1991; 23: 1363-4
44. Hricik DE, Lautman J, Bartucci MR, et al. Variable effects of steroid withdrawal on blood pressure reduction in cyclosporine-treated renal transplant recipients. Transplantation 1992; 53: 1232-5
45. Kasiske BL, Umen AJ. Persistent hyperlipidemia in renal transplant recipients. Medicine 1987; 66: 309-16
46. Lowry RP, Soltys G, Mangel R, et al. Type II hyperlipoproteinemia, hyperbetalipoproteinemia and hyperalphaproteinemia following renal transplantation: prevalence and precipitating factors. Transplant Proc 1987; 19: 2229-32
47. Hricik DE, Mayes JT, Schulak JA. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. Am J Kidney Dis 1991; 28: 353-8
48. Bagdade JD, Albers JJ. Plasma high-density lipoprotein concentrations in chronic hemodialysis and renal transplant patients. N Engl J Med 1977; 296: 1436-9
49. Gokal R, Mann JI, Moore RA, et al. Hyperlipidemia following renal transplantation. Q J Med 1979; 48: 507-17
50. Ibels LS, Alfrey AC, Weil R. Hyperlipidemia in adult, pediatric, and diabetic renal transplant recipients. Am J Med 1978; 64: 634-42
51. Ghose P, Evans DB, Tomlinson SA, et al. Plasma lipids following renal transplantation. Transplantation 1973; 15: 521-2
52. Cattran DC, Steiner G, Wilson DR, et al. Hyperlipidemia after renal transplantation: natural history and pathophysiology. Ann Intern Med 1979; 91: 554-9
53. Kasiske BL, Tortorice KL, Heim-Duthoy KL, et al. The adverse impact of cyclosporine on serum lipids in renal transplant recipients. Am J Kidney Dis 1991; 17: 700-7
54. Hricik DE, Bartucci MR, Mayes JT, et al. The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients. Transplantation 1992; 54: 868-71
55. Ballantyne CM, Podet EJ, Pattsch WP, et al. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 1989; 262: 53-6
56. Hariharan S, Schroeder TJ, Weiskittel P, et al. Prednisone with-drawal in HLA identical, one haplotype matched live related donor and cadaver renal transplant recipients. Kidney Int 1993; 43 Suppl.: S30-5
57. Olefsky JM, Kimmerling G. Effects of glucocorticoids on carbohydrate metabolism. Am J Med Sci 1976; 271: 202-10
58. Hahn HJ, Laube F, Lucke S, et al. Toxic effects of cyclosporine on the endocrine pancreas of Wistar rats. Transplantation 1986; 41: 44-7
59. Yale JF, Chamelian M, Courchesne S, et al. Peripheral insulin resistance and decreased insulin secretion after cyclosporine A treatment. Transplant Proc 1988; 20 (Suppl. 3): 985-7
60. Ost L, Tyden G, Fehrman I. Impaired glucose tolerance in cyclosporine-prednisolone-treated renal graft recipients. Transplantation 1988; 46: 370-2
61. Yoshimura N, Nakai I, Ohmori Y, et al. Effect of cyclosporine on the endocrine and exocrine pancreas in kidney transplant recipients. Am J Kidney Dis 1988; 12: 11-7
62. Roth D, Milgrom M, Esquenazi V, et al. Posttransplant hyperglycemia: increased incidence in cyclosporine-treated renal allograft recipients. Transplantation 1989; 47: 278-81
63. Mejia G, Arbelaez M, Henao JE, et al. Cyclosporine-associated diabetes mellitus in renal transplants. Clin Transplant 1989; 3: 260-5
64. Boudreaux JP, McHugh L, Canafax DM, et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation 1987; 44: 376-81
65. Hricik DE, Bartucci MR, Moir EJ, et al. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation 1991; 51: 374-7
66. Fabrega AJ, Cohan J, Meslar P, et al. Effects of steroid withdrawal on long-term renal allograft recipients with post transplantation diabetes mellitus. Surgery 1994; 116: 792-7
67. Fabrega AJ, Meslar P, Cohan J, et al. Long-term (24-month) follow-up of steroid withdrawal in renal allograft recipients with posttransplant diabetes mellitus. Transplantation 1995; 60: 1612-4
68. Monnier VM, Vishwanath V, Frank KE, et al. Relationship between complications of type 1 diabetes mellitus and collagen-linked fluorescence. N Engl J Med 1986; 314: 403-8
69. Hricik DE, Schulak JA, Sell DR, et al. Effects of kidney or kidney-pancreas transplantation on plasma pentosidine. Kidney Int 1993; 43: 398-403
70. Maiorca R, Cristinelli L, Brunori G, et al. Prospective controlled trial of steroid withdrawal after six months in renal allograft patients treated with cyclosporine. Transplant Proc 1988; 20 (Suppl. 3): 121-5
71. Ratcliffe PJ, Firth JD, Higgins RM, et al. Randomized controlled trial of complete steroid withdrawal in renal transplant patients receiving triple immunosuppression. Transplant Proc 1993; 25: 590
72. Sinclair NR, Canadian Multicenter Transplant Study Group. Low dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. Can Med Assoc J 1992; 147: 645-55
73. Hilbrands LB, Hoitsma AJ, Koene RAP. Randomized, prospective trial of cyclosporine monotherapy versus azathioprine-prednisone from three months after renal transplantation. Transplantation 1996; 61: 1038-46
74. Flechner SM, Kerman RH, Van Buren CT, et al. The use of cyclosporine in living-related renal transplantation: donor-specific hyporesponsiveness and steroid withdrawal. Transplantation 1984; 38: 685-90
75. Cristinelli C, Brunori G, Sett G, et al. Withdrawal of methyl-prednisolone at the sixth month in renal transplant recipients treated with cyclosporine. Transplant Proc 1987; 19: 2021-3
76. O'Connell P, D'Apice A, Walker R, et al. Cessation of steroids in renal allograft recipients on combined cyclosporine A, azathioprine, and prednisolone. Transplant Proc 1988; 20: 11-3
77. Walker RG, D'Apice AJF, Powell HR, et al. Triple low-dose immunosuppression with cessation of steroids in pediatric renal transplantation. Transplant Proc 1988; 20: 7-10
78. Hricik DE, O'Toole MA, Schulak JA, et al. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis. J Am Soc Nephrol 1993; 4: 1300-5
79. Gulanikar AC, Belitsky P, MacDonald AS, et al. Randomized controlled trial of steroids versus no steroids in stable cyclosporine-treated renal graft recipients. Transplant Proc 1991; 23: 990-1
80. Albert FW, Schmidt U. Cyclosporine therapy with or without steroids in cadaveric kidney transplantation - a prospective randomized one-center study. Transplant Proc 1987; 17: 2669-70
81. Thiel G, Harder F, Loertscher R, et al. Cyclosporine alone or in combination with prednisone in cadaveric renal transplantation. Transplant Proc 1984; 16: 1187-90
82. Johnson RWG, Mallick NP, Bakran A, et al. Cadaveric renal transplantation without maintenance steroids. Transplant Proc 1989; 21: 1581-2
83. Ikemiyashiro D, Aziz S, Venkat KK, et al. Long-term results of complete corticosteroid withdrawal in cyclosporine-treated one haplotype match living related transplant recipients [abstract]. Proc Am Soc Transplant Phys 1993: 73
84. First MR, Munda R, Kant KS, et al. Steroid withdrawal following HLA-identical related donor transplantation. Transplant Proc 1981; 13: 319-22
85. Roberti I, Reisman L, Lieberman KV, et al. Risk of steroid withdrawal in pediatric renal allograft recipients (a 5-year follow-up). Clin Transplant 1994; 8: 405-8
86. Andreu J, Campistol JM, Oppenheimer F, et al. Improved results in elderly renal transplants without prophylactic steroids. Clin Transplant 1991; 5: 3-6
87. Opelz G. Effect of the maintenance immunosuppressive drug regimen on kidney transplant outcome. Transplantation 1994; 58: 443-6
88. Tarantino A, Montagnino G, Ponticelli C. Corticosteroids in kidney transplant recipients: safety issues and timing of discontinuation. Drug Saf 1995; 13: 145-56
89. Ponticelli C, Tarantino A, Montagnino G. Controlled trials with cyclosporine in kidney transplantation. Transplant Proc 1994; 26: 2490-2
90. Offerman G, Schwarz A, Krause PH. Long-term effects of steroid withdrawal in kidney transplantation. Transplant Int 1993; 6: 290-2
91. Isonniemi HM, Krogerus L, von Willebrand E, et al. Histopathological findings in well-functioning, long-term renal allografts. Kidney Int 1992; 41: 155-60
92. Kupin W, Nakleh R, Lee M, et al. Separate risk factors for the development of transplant glomerulopathy vs. chronic tubulointerstitial rejection [abstract]. Proc Am Soc Transplant Phys 1996: 144
93. Ghandour FZ, Knauss TC, Schulak JA, et al. Influence of steroid withdrawal on proteinuria in renal allograft recipients. Clin Transplant 1997. In press
94. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752-7
95. Basadonna GP, Matas AJ, Gillingham KJ, et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993; 55: 993-5
96. Elli A, Rivolta R, Quarto Dipalo F, et al. A randomized trial of deflazacort versus 6-methylprednisolone in renal transplantation - immunosuppressive activity and side effects. Transplantation 1993; 55: 209-12